Objective To study the efficacy and safety of early intratracheal administration of budesonide combined with pulmonary surfactant (PS) in preventing bronchopulmonary dysplasia (BPD). Methods A prospective randomized controlled trial was designed. A total of 122 infants with a high risk of BPD who were admitted to the neonatal intensive care unit of the Third Affiliated Hospital of Zhengzhou University from January to July 2021 were enrolled. The infants were randomly divided into a conventional treatment group with 62 infants (treated with PS alone at an initial dose of 200 mg/kg, followed by a dose of 100 mg/kg according to the condition of the infant) and an observation group with 60 infants (treated with PS at the same dose as the conventional treatment group, with the addition of budesonide 0.25 mg/kg for intratracheal instillation at each time of PS application). The two groups were compared in terms of the times of PS use, ventilator parameters at different time points, oxygen inhalation, incidence rate and severity of BPD, incidence rate of complications, and tidal breathing pulmonary function at the corrected gestational age of 40 weeks. Results Compared with the conventional treatment group, the observation group had a significantly lower proportion of infants using PS for two or three times (P<0.05). Compared with the conventional treatment group, the observation group had a significantly lower fraction of inspired oxygen at 24 and 48 hours and 3, 7, and 21 days after administration, significantly shorter durations of invasive ventilation, noninvasive ventilation, ventilator application, and oxygen therapy, a significantly lower incidence rate of BPD, and a significantly lower severity of BPD (P<0.05). There was no significant difference in the incidence rate of glucocorticoid-related complications between the two groups (P>0.05). Conclusions Compared with PS use alone in preterm infants with a high risk of BPD, budesonide combined with PS can reduce repeated use of PS, lower ventilator parameters, shorten the duration of respiratory support, and reduce the incidence rate and severity of BPD, without increasing the incidence rate of glucocorticoid-related complications.
Key words
Bronchopulmonary dysplasia /
Budesonide /
Pulmonary surfactant /
Preterm infant
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Gallini F, Coppola M, De Rose DU, et al. Neurodevelopmental outcomes in very preterm infants: the role of severity of bronchopulmonary dysplasia[J]. Early Hum Dev, 2021, 152: 105275. PMID: 33227635. DOI: 10.1016/j.earlhumdev.2020.105275.
2 史源, 王建辉. 早产儿慢性肺功能不全解读[J]. 中华儿科杂志, 2019, 57(12): 974-977. PMID: 31795570. DOI: 10.3760/cma.j.issn.0578-1310.2019.12.018.
3 石晶. 糖皮质激素疗法防治支气管肺发育不良研究进展[J]. 中华实用儿科临床杂志, 2018, 33(2): 85-88. DOI: 10.3760/cma.j.issn.2095-428X.2018.02.002.
4 Kong XY, Xu FD, Wu R, et al. Neonatal mortality and morbidity among infants between 24 to 31 complete weeks: a multicenter survey in China from 2013 to 2014[J]. BMC Pediatr, 2016, 16(1): 174. PMID: 27809893. PMCID: PMC5094017. DOI: 10.1186/s12887-016-0716-5.
5 江苏省新生儿重症监护病房母乳质量改进临床研究协作组. 多中心回顾性分析极低及超低出生体重儿支气管肺发育不良的临床特点及高危因素[J]. 中华儿科杂志, 2019, 57(1): 33-39. PMID: 30630229. DOI: 10.3760/cma.j.issn.0578-1310.2019.01.009.
6 左敬叶, 王艺睿, 杨宇婷. 早产儿支气管肺发育不良的发病机制研究进展[J]. 国际儿科学杂志, 2019, 46(11): 831-834. DOI: 10.3760/cma.j.issn.1673-4408.2019.11.014.
7 Mhanna C, Pinto M, Koechley H, et al. Postnatal glucocorticoid use impacts renal function in VLBW neonates[J]. Pediatr Res, 2021: 1-6. PMID: 34400792. PMCID: PMC8366742. DOI: 10.1038/s41390-021-01624-1. Epub ahead of print.
8 Yeh TF, Chen CM, Wu SY, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med, 2016, 193(1): 86-95. PMID: 26351971. DOI: 10.1164/rccm.201505-0861OC.
9 中华医学会儿科学分会新生儿学组, 中华儿科杂志编辑委员会. 中国新生儿肺表面活性物质临床应用专家共识(2021版)[J]. 中华儿科杂志, 2021, 59(8): 627-632. PMID: 34333913. DOI: 10.3760/cma.j.cn112140-20210329-00261.
10 Chen CM, Chang CH, Chao CH, et al. Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration[J]. Drug Deliv, 2019, 26(1): 604-611. PMID: 31204848. PMCID: PMC6586100. DOI: 10.1080/10717544.2019.1618418.
11 Flayer CH, Ge MQ, Hwang JW, et al. Ozone inhalation attenuated the effects of budesonide on Aspergillus fumigatus-induced airway inflammation and hyperreactivity in mice[J]. Front Immunol, 2019, 10: 2173. PMID: 31572383. PMCID: PMC6753328. DOI: 10.3389/fimmu.2019.02173.
12 Yang CF, Lin CH, Chiou SY, et al. Intratracheal budesonide supplementation in addition to surfactant improves pulmonary outcome in surfactant-depleted newborn piglets[J]. Pediatr Pulmonol, 2013, 48(2): 151-159. PMID: 22489085. DOI: 10.1002/ppul.22564.
13 Gie AG, Regin Y, Salaets T, et al. Intratracheal budesonide/surfactant attenuates hyperoxia-induced lung injury in preterm rabbits[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 319(6): L949-L956. PMID: 32903026. DOI: 10.1152/ajplung.00162.2020.
14 Yang CF, Jeng MJ, Soong WJ, et al. Acute pathophysiological effects of intratracheal instillation of budesonide and exogenous surfactant in a neonatal surfactant-depleted piglet model[J]. Pediatr Neonatol, 2010, 51(4): 219-226. PMID: 20713286. DOI: 10.1016/S1875-9572(10)60042-3.
15 Dani C. Intratracheal budesonide/surfactant for preventing bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med, 2016, 194(1): 123. PMID: 27367894. DOI: 10.1164/rccm.201603-0497LE.
16 Yeh TF, Chen CM. Reply: intratracheal budesonide/surfactant for preventing bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med, 2016, 194(1): 123-124. PMID: 27367893. DOI: 10.1164/rccm.201603-0587LE.
17 邓黎静, 彭华保, 龚晓琴. 布地奈德联合肺表面活性物质治疗重症呼吸窘迫综合征对支气管肺发育不良的影响[J]. 中华新生儿科杂志(中英文), 2017, 32(5): 361-364. DOI: 10.3760/cma.j.issn.2096-2932.2017.05.009.
18 余静, 喻婷婷. 不同剂型布地奈德联合肺泡表面活性物质治疗新生儿呼吸窘迫综合征的临床分析[J]. 中华肺部疾病杂志(电子版), 2018, 11(4): 416-420. DOI: 10.3877/cma.j.issn.1674-6902.2018.04.006.
19 张慧, 马源培, 武慧, 等. 肺表面活性物质联合布地奈德治疗早产儿呼吸窘迫综合征改善短期呼吸系统合并症的疗效[J]. 中国生育健康杂志, 2021, 32(2): 127-130. DOI: 10.3969/j.issn.1671-878X.2021.02.006.
20 Moschino L, Nardo D, Bonadies L, et al. Intra-tracheal surfactant/budesonide versus surfactant alone: comparison of two consecutive cohorts of extremely preterm infants[J]. Pediatr Pulmonol, 2021, 56(7): 2114-2124. PMID: 33942570. PMCID: PMC8251959. DOI: 10.1002/ppul.25415.
21 Yao YL, Zhang GF, Wang F, et al. Efficacy of budesonide in the prevention and treatment of bronchopulmonary dysplasia in premature infants and its effect on pulmonary function[J]. Am J Transl Res, 2021, 13(5): 4949-4958. PMID: 34150079. PMCID: PMC8205685.
22 杨波, 雷红林, 任漪, 等. 肺表面活性物质联合布地奈德气管注入治疗早产儿呼吸窘迫综合征的随机对照研究[J]. 中华新生儿科杂志, 2021, 36(2): 33-37. DOI: 10.3760/cma.j.issn.2096-2932.2021.02.006.
23 Sucasas Alonso A, Pértega Díaz S, Sáez Soto R, et al. Epidemiology and risk factors for bronchopulmonary dysplasia in prematures infants born at or less than 32 weeks of gestation[J]. An Pediatr (Engl Ed), 2021, S1695-4033(21)00153-3. PMID: 33814331. DOI: 10.1016/j.anpedi.2021.03.002. Epub ahead of print.
24 Rutkowska M, Ho?ejowski R, Helwich E, et al. Severe bronchopulmonary dysplasia—incidence and predictive factors in a prospective, multicenter study in very preterm infants with respiratory distress syndrome[J]. J Matern Fetal Neonatal Med, 2019, 32(12): 1958-1964. PMID: 29295665. DOI: 10.1080/14767058.2017.1422711.
25 储晓彬, 晏路标, 韩树萍, 等. 肺表面活性物质联合布地奈德干预治疗对伴呼吸窘迫综合征的低出生体质量儿心功能的保护作用[J]. 实用儿科临床杂志, 2012, 27(14): 1116-1118. DOI: 10.3969/j.issn.1003-515X.2012.14.024.
26 晏路标, 韩树萍, 储晓彬, 等. 布地奈德联合肺表面活性物质对机械通气极低出生体质量儿脑损伤的保护作用[J]. 中华实用儿科临床杂志, 2014, 29(6): 419-423. DOI: 10.3760/cma.j.issn.2095-428X.2014.06.007.
27 Kuo HT, Lin HC, Tsai CH, et al. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants[J]. J Pediatr, 2010, 156(4): 537-541. PMID: 20138301. DOI: 10.1016/j.jpeds.2009.10.049.
28 吉玲, 马莉雅, 黄娜娜. 不同胎龄早产儿潮气呼吸肺功能的测定及分析[J]. 中国当代儿科杂志, 2015, 17(5): 449-452. PMID: 26014693. DOI: 10.7499/j.issn.1008-8830.2015.05.007.
29 王博, 段翌, 孙莹, 等. 胎龄<34周呼吸窘迫综合征早产儿纠正年龄40周时肺功能监测[J]. 中华急诊医学杂志, 2017, 26(6): 627-631. DOI: 10.3760/cma.j.issn.1671-0282.2017.06.005.
30 路星星, 朱玲玲, 赵雪琴, 等. KL-6 FGF-10测定联合潮气呼吸肺功能在早产儿中的应用[J]. 中国妇幼保健, 2021, 36(8): 1776-1778. DOI: 10.19829/j.zgfybj.issn.1001-4411.2021.08.022.
PDF(795 KB)
